Insights from ACR 2025, including anticipated presentations, key takeaways, and how emerging research in SLE may affect ...

Objective Lupus nephritis (LN) is a prevalent renal manifestation in patients with SLE, with kidney biopsy remaining the gold ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

One-month post-launch, Gazyva’s perceived degree of advance exceeds benchmarks achieved by GSK’s Benlysta and Aurinia’s Lupkynis at comparable post-launch time points.EXTON, PA, Nov. 19, 2025 (GLOBE ...

United States real-world studies highlight the importance of controlling lupus nephritis to improve patient prognosis.

MMF induction is a viable alternative to cyclophosphamide for treating mixed proliferative lupus nephritis in children. Oral mycophenolate mofetil (MMF) is as effective as intravenous cyclophosphamide ...

Recent approvals of Benlysta and Lupkynis highlight a shift towards targeted therapies with improved profiles. Despite challenges like high costs and heterogeneous disease presentation, opportunities ...

Spherix Global Insights has released the first wave of Launch Dynamix™: Gazyva in Lupus Nephritis, providing the earliest independent read on the ...